SNG 100
Alternative Names: SNG-100Latest Information Update: 12 Nov 2020
At a glance
- Originator Seanergy Dermatology
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Atopic dermatitis
Most Recent Events
- 05 Nov 2020 Seanergy Dermatology plans a phase I trial for Atopic dermatitis (In children, In adolescents, In adults, In the elderly) (Topical, Cream) in January 2021 (NCT04615962)
- 01 Nov 2020 Preclinical trials in Atopic dermatitis in Israel (Topical) before November 2020